These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19556212)

  • 1. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study.
    Singh RP; Fu EX; Smith SD; Williams DR; Kaiser PK
    Br J Ophthalmol; 2009 Oct; 93(10):1353-8. PubMed ID: 19556212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
    Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
    Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.